他汀类药物后脂质治疗学：综述
Poststatin Lipid Therapeutics: A Review.
作者信息
Jia Xiaoming, Lorenz Patrick, Ballantyne Christie M
机构信息
BAYLOR COLLEGE OF MEDICINE, HOUSTON, TEXAS.
出版信息
Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):32-38. doi: 10.14797/mdcj-15-1-32.
Abstract
Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). Statins remain the first-line therapy for patients with elevated LDL-C and increased risk. However, many at-risk patients do not achieve adequate LDL-C lowering with statin monotherapy or do not tolerate statins because of side effects. Recent cardiovascular outcome trials involving ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated efficacy of nonstatin therapies in further reducing LDL-C levels and ASCVD risk. This review highlights the available nonstatin therapeutic options and explores important novel therapeutic approaches currently under development.
摘要
低密度脂蛋白胆固醇（LDL-C）是动脉粥样硬化性心血管疾病（ASCVD）公认的危险因素。他汀类药物仍然是LDL-C升高且风险增加患者的一线治疗药物。然而，许多高危患者使用他汀类药物单药治疗无法充分降低LDL-C水平，或者由于副作用而不耐受他汀类药物。最近涉及依折麦布和前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂的心血管结局试验证明了非他汀类疗法在进一步降低LDL-C水平和ASCVD风险方面的疗效。本综述重点介绍了现有的非他汀类治疗选择，并探讨了目前正在研发的重要新型治疗方法。
相似文献
1
Poststatin Lipid Therapeutics: A Review.他汀类药物后脂质治疗学：综述
Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):32-38. doi: 10.14797/mdcj-15-1-32.
2
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
3
Identifying Patients for Nonstatin Therapy.确定非他汀类药物治疗的患者。
Rev Cardiovasc Med. 2018;19(S1):S1-S8. doi: 10.3909/ricm19S1S0004.
4
Alirocumab as add-on therapy to statins: current evidence and clinical potential.阿利西尤单抗作为他汀类药物的附加疗法：当前证据及临床潜力。
Ther Adv Cardiovasc Dis. 2018 Jul;12(7):191-202. doi: 10.1177/1753944718775352. Epub 2018 May 24.
5
Implications for REDUCE IT in clinical practice.对临床实践中 REDUCE IT 的启示。
Prog Cardiovasc Dis. 2019 Sep-Oct;62(5):395-400. doi: 10.1016/j.pcad.2019.11.003. Epub 2019 Nov 9.
6
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.基于贝叶斯网络的 PCSK9 抑制剂、他汀类药物和依折麦布联合或不联合他汀类药物用于心血管结局的荟萃分析。
Eur J Prev Cardiol. 2018 May;25(8):844-853. doi: 10.1177/2047487318766612. Epub 2018 Mar 23.
7
Nonstatin Therapy for Dyslipidemia.血脂异常的非他汀类治疗
Circ Res. 2018 Oct 12;123(9):1036-1038. doi: 10.1161/CIRCRESAHA.118.313829.
8
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂与心血管风险：对傅里叶试验的进一步分析是否提示降脂治疗靶点的变化？
High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.
9
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.低密度脂蛋白胆固醇≥190mg/dL患者降脂治疗使用情况的差异：来自国家心血管数据注册库 - 实践创新与临床卓越注册库的见解
Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652.
10
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.在极高危患者中，低密度脂蛋白胆固醇水平较低与心血管事件之间的关联：依洛尤单抗与对照的 9 项 ODYSSEY 试验的汇总分析。
Atherosclerosis. 2019 Sep;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. Epub 2019 Jul 12.
引用本文的文献
1
Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review.用于管理血脂异常的降脂药物：一项叙述性综述。
Cureus. 2024 Jul 23;16(7):e65202. doi: 10.7759/cureus.65202. eCollection 2024 Jul.
2
Investigating the physicochemical characteristics and importance of insoluble dietary fiber extracted from legumes: An in-depth study on its biological functions.研究从豆类中提取的不溶性膳食纤维的理化特性及其重要性：对其生物学功能的深入研究。
Food Chem X. 2024 Apr 28;22:101424. doi: 10.1016/j.fochx.2024.101424. eCollection 2024 Jun 30.
3
Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis.前蛋白转化酶枯草溶菌素9抑制剂对心血管疾病高风险和极高风险患者血脂水平的影响：一项系统评价和荟萃分析
Cardiol Res Pract. 2022 Apr 26;2022:8729003. doi: 10.1155/2022/8729003. eCollection 2022.
4
Beneficial Effects of Three Dietary Cyclodextrins on Preventing Fat Accumulation and Remodeling Gut Microbiota in Mice Fed a High-Fat Diet.三种膳食环糊精对高脂饮食小鼠预防脂肪堆积和重塑肠道微生物群的有益作用。
Foods. 2022 Apr 13;11(8):1118. doi: 10.3390/foods11081118.
5
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.基于抗体的动脉粥样硬化和心血管疾病治疗方法。
Int J Mol Sci. 2021 May 28;22(11):5770. doi: 10.3390/ijms22115770.
6
Dietary Fiber, Atherosclerosis, and Cardiovascular Disease.膳食纤维、动脉粥样硬化与心血管疾病。
Nutrients. 2019 May 23;11(5):1155. doi: 10.3390/nu11051155.
本文引用的文献
1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.依洛尤单抗与急性冠脉综合征后的心血管结局。
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
2
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.在不能耐受他汀类药物的高胆固醇血症患者中，添加苯扎贝特酸与依折麦布联合治疗的疗效和安全性：一项随机、安慰剂对照研究。
Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12.
3
Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.载脂蛋白(a)降低后 LDL-C、估计真实 LDL-C、载脂蛋白 B-100 和 PCSK9 水平的关系。
采用反义寡核苷酸。
J Clin Lipidol. 2018 May-Jun;12(3):702-710. doi: 10.1016/j.jacl.2018.02.014. Epub 2018 Mar 1.
4
Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.《2018年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31.
5
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2017 年对 2016 年美国心脏病学会专家共识决策途径的重点更新：非他汀类药物在降低动脉粥样硬化性心血管疾病风险管理中的作用：美国心脏病学会专家组的专家共识决策途径报告。
J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.
6
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.血管生成素样蛋白3的基因和药物失活与心血管疾病
N Engl J Med. 2017 Jul 20;377(3):211-221. doi: 10.1056/NEJMoa1612790. Epub 2017 May 24.
7
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.依洛尤单抗在 LDL 胆固醇升高的高心血管风险患者中的应用。
N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17.
8
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
9
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.动脉粥样硬化血栓形成风险分层与依折麦布用于二级预防。
J Am Coll Cardiol. 2017 Feb 28;69(8):911-921. doi: 10.1016/j.jacc.2016.11.070.
10
Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.脂蛋白(a)与前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
J Thorac Dis. 2017 Jan;9(1):E78-E82. doi: 10.21037/jtd.2017.01.40.
Zotero 插件